Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
investigational drug |
| gptkbp:activeIngredient |
human growth hormone
|
| gptkbp:alternativeName |
lonapegsomatropin
|
| gptkbp:brand |
gptkb:Skytrofa
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:developedBy |
gptkb:Ascendis_Pharma
|
| gptkbp:dosingFrequency |
once weekly
|
| gptkbp:drugClass |
endocrine therapy
|
| gptkbp:form |
prodrug
|
| gptkbp:halfLife |
long-acting
|
| https://www.w3.org/2000/01/rdf-schema#label |
TransCon hGH
|
| gptkbp:indication |
adult growth hormone deficiency
pediatric growth hormone deficiency |
| gptkbp:intendedUse |
growth hormone deficiency
|
| gptkbp:mechanismOfAction |
sustained release of hGH
|
| gptkbp:regulates |
approved in US
approved in EU |
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:trialSponsor |
gptkb:Ascendis_Pharma
|
| gptkbp:bfsParent |
gptkb:Ascendis_Pharma_A/S
|
| gptkbp:bfsLayer |
7
|